VYNE Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements Of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(3,585) | $(8,611) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 6 | 6 |
| Stock-based compensation | 474 | 763 |
| Amortization of premium or discount on marketable securities | (18) | (324) |
| Changes in operating assets and liabilities: | ||
| Trade receivables, prepaid expenses and other assets and operating lease right-of-use assets | 202 | (768) |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | (1,160) | (2,490) |
| Operating lease liabilities | — | (37) |
| Net cash used in operating activities | (4,081) | (11,461) |
| Cash Flows From Investing Activities: | ||
| Proceeds from sale and maturity of marketable securities | 4,700 | 33,600 |
| Purchases of marketable securities | — | (13,769) |
| Net cash provided by investing activities | 4,700 | 19,831 |
| Cash Flows From Financing Activities: | ||
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | (15) | (87) |
| Net cash used in financing activities | (15) | (87) |
| Increase in cash and cash equivalents | 604 | 8,283 |
| Cash and cash equivalents at beginning of the period | 24,027 | 19,926 |
| Cash and cash equivalents at end of the period | $24,631 | $28,209 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.